Market News AIOpen the app

Tenax Therapeutics, Inc. says it is stopping new sign-ups for its LEVEL-2 clinical trial for now.

TrialRead the original at SEC EDGAR
Neutral

Tenax paused LEVEL-2 enrollment to focus on patients more likely to improve their exercise tolerance. That possible benefit is balanced by the study delay, and the filing reports no LEVEL-2 results.

TENX · Tenax Therapeutics, Inc.

AI read · Neutral

The AI's read

The change could focus LEVEL-2 on patients more likely to improve, based on lessons from the completed Phase 3 trial. But pausing enrollment delays the study, and Tenax has only requested an FDA meeting. The filing reports no LEVEL-2 results, so these facts do not clearly change the outlook.

Get alerts for TENX

Follow Tenax Therapeutics, Inc. (TENX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TENX
Free on the App Store and Google Play, or on the web.